Approaches to the primary and secondary prevention of cerebral complications in patients with arterial hypertension and multifocal atherosclerosis

Introduction. Patients with arterial hypertension (AH) and multifocal atherosclerosis (MFA) remain at a high risk of recurrent ischemic events.
Aim. To show the effectiveness of using dual antithrombotic therapy (acetylsalicylic acid (ASA) 100 mg per day + rivaroxaban 2.5 mg twice daily) in patients with AH and MFA.
Materials and methods. The study included 219 patients (mean age 59 ± 8 years) with controlled AH and MFA, 110 of them were stage 1–2 AH (group 1), 109 were stage 3 AH and a history of atherothrombotic ischemic stroke (IS) (group 2). Coagulation hemostasis, high‐sensitivity reactive protein (hs‐CRP) and interleukin‐6 (IL-6) levels were monitored in all patients. Patients were randomized into the main group – ASA 100 mg/day + rivaroxaban 2.5 mg 2 times a day and the comparison group – ASA 100 mg/day. The treatment period was 6 months. Quality of life (QOL) was assessed using the short form of the SF-36 questionnaire before randomization and after 6 months of treatment. After 18 months, the primary endpoints (acute vascular accident, cardiovascular death, hospitalization) were evaluated.
Results. The addition of rivaroxaban to ASA led to an improvement in local and global indicators of hemostasis and markers of inflammation, an increase in QOL indicators for physical and mental components, and a reduction in the risk of primary endpoints. When taking rivaroxaban, a low incidence of side effects was recorded: minor bleeding was observed in 4 (3.7%) patients on ASA + rivaroxaban therapy. They were manifested by bleeding from the gums and hemorrhoids and did not require special treatment. No major bleeding has been reported in any patient.
Conclusions. The use of dual antiplatelet therapy (ASA + rivaroxaban) leads to an improvement in hemostasis, markers of inflammation and QOL, as well as to a reduction in the risk of cardiovascular complications.

1. Vanuzzo D. The epidemiological concept of residual risk. Intern Emerg Med. 2011;6(Suppl. 1):45–51. https://doi.org/10.1007/s11739-011-0669-5.

2. Biccirè FG, Farcomeni A, Gaudio C, Pignatelli P, Tanzilli G, Pastori D. D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: asystematic review and metanalysis. Thromb J. 2021;19(1):102. https://doi.org/10.1186/s12959-021-00354-y.

3. Weitz JI, Angiolillo DJ, Geisler T, Heitmeier S. Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. Thromb Haemost. 2020;120(8):1147–1158. https://doi.org/10.1055/s-0040-1713376.

4. Olie RH, van der Meijden PEJ, Ten Cate H. The coagulation system in atherothrombosis: Implications for new therapeutic strategies. Res Pract Thromb Haemost. 2018;2(2):188–198. https://doi.org/10.1002/rth2.12080.

5. White H. Targeting therapy to the fibrin-mediated pathophysiology of acute coronary syndrome. Clin Appl Thromb Hemost. 2014;20(5):516–523. https://doi.org/10.1177/1076029612472551.

6. Weitz JI. Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome. Thromb Haemost. 2014;112(5):924–931. https://doi.org/10.1160/TH14-03-0265.

7. Posma JJ, Grover SP, Hisada Y, Owens AP 3rd, Antoniak S, Spronk HM, Mackman N. Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases. Arterioscler Thromb Vasc Biol. 2019;39(1):13–24. https://doi.org/10.1161/ATVBAHA.118.311655.

8. Held C, White HD, Stewart RAH, Budaj A, Cannon CP, Hochman JS et.al. STABILITY Investigators. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc. 2017;6(10):e005077. https://doi.org/10.1161/JAHA.116.005077.

9. Tian Y, Jing J, Wang H, Wang A, Zhang Y, Jiang Y et al. Association of Polyvascular Disease and Elevated Interleukin-6 With Outcomes in Acute Ischemic Stroke or Transient Ischemic Attack. Front Neurol. 2021;12:661779. https://doi.org/10.3389/fneur.2021.661779.

10. Neyazi A, Mohammadi AQ, Neyazi M, Timilsina S, Padhi BK, Griffiths MD. Hypertension, depression, and health-related quality of life among hospitalized patients in Afghanistan. J Hum Hypertens. 2024;38(6):529–537. https://doi.org/10.1038/s41371-024-00914-5.

11. Sumin AN, Mos’kin MG, Bezdenezhnykh AV, Korok EV, Shcheglova AV, Barbarash OL. Stenosis in noncoronary areas and life quality in ischemic heart disease. Russian Journal of Cardiology. 2015;(7):104–109. (In Russ.) https://doi.org/10.15829/1560-4071-2015-7-104-109.

12. Jannati S, Patnaik R, Banerjee Y. Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling. Int J Mol Sci. 2024;25(16):8727. https://doi.org/10.3390/ijms25168727.

13. Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3-3786.

14. Ezhov MV, Kukharchuk VV, Sergienko IV, Alieva AS, Antsiferov MB, Ansheles AA et al. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology. 2023;28(5):5471. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5471.

15. Liegl G, H Fischer F, N Martin C, Rönnefarth M, Blumrich A, Ahmadi M et al. Converting PROMIS®-29 v2.0 profile data to SF-36 physical and mental component summary scores in patients with cardiovascular disorders. Health Qual Life Outcomes. 2024;22(1):64. https://doi.org/10.1186/s12955-024-02277-4.

16. Meccanici F, Thijssen CGE, Gökalp AL, Bom AW, Geuzebroek GSC, Ter Woorst JF et al. Long-Term Health-Related Quality of Life following Acute Type A Aortic Dissection with a Focus on Male-Female Differences: A Cross Sectional Study. J Clin Med. 2024;13(8):2265. https://doi.org/10.3390/jcm13082265.

17. Ranganathan P, Aggarwal R, Pramesh CS. Common pitfalls in statistical analysis: Odds versus risk. Perspect Clin Res. 2015;6(4):222–224. https://doi.org/10.4103/2229-3485.167092.

18. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. https://doi.org/10.1136/bmj.a1840.

19. Vallejo-Vaz AJ, Dharmayat KI, Nzeakor N, Carrasco CP, Fatoba ST, Fonseca MJ et al. Recurrent cardiovascular and limb events in 294,428 patients with coronary or peripheral artery disease or ischemic stroke on antiplatelet monotherapy: The RESRISK cohort study. Atherosclerosis. 2024;398:118589. https://doi.org/10.1016/j.atherosclerosis.2024.118589.

20. Vorobyova NM. Acetylsalicylic acid resistance: relevance of correct dosage form. Meditsinskiy Sovet. 2013;(9):76–81. (In Russ.) Available at: https://www.med-sovet.pro/jour/article/view/1107.

21. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O et al. COMPASS investigators. rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–1330. https://doi.org/10.1056/NEJMoa1709118.

22. Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS et al. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018;199:83–89. https://doi.org/10.1016/j.ahj.2018.01.011.

23. Hernández JL, Lozano FS, Riambau V, Almendro-Delia M, Cosín-Sales J, Bellmunt-Montoya S et al. Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial. Drugs Context. 2020;9:2020-5-5. https://doi.org/10.7573/dic.2020-5-5.

24. Ringwala SM, Dibattiste PM, Schneider DJ. Effects on platelet function of a direct acting antagonist of coagulation factor Xa. J Thromb Thrombolysis. 2012;34(3):291–296. https://doi.org/10.1007/s11239-012-0727-5.

25. Posthuma JJ, Posma JJN, van Oerle R, Leenders P, van Gorp RH, Jaminon AMG et al. Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice. Sci Rep. 2019;9(1):3909. https://doi.org/10.1038/s41598-019-40602-w.

26. Lou X, Yu Z, Yang X, Chen J. Protective effect of rivaroxaban on arteriosclerosis obliterans in rats through modulation of the toll-like receptor 4/NF-κB signaling pathway. Exp Ther Med. 2019;18(3):1619–1626. https://doi.org/10.3892/etm.2019.7726.

27. Wypasek E, Natorska J, Mazur P, Kopytek M, Gawęda B, Kapusta P et al. Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves. Vascul Pharmacol. 2020;130:106679. https://doi.org/10.1016/j.vph.2020.106679.

28. Ding Y, Li X, Zhou M, Cai L, Tang H, Xie T et al. Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation. Vascul Pharmacol. 2021;136:106818. https://doi.org/10.1016/j.vph.2020.106818.

29. Kirchhof P, Ezekowitz MD, Purmah Y, Schiffer S, Meng IL, Camm AJ et al. Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial. TH Open. 2020;4(1):e20-e32. https://doi.org/10.1055/s-0040-1701206.

30. Nekrasov AA, Timoschenko ES, Nekrasova TA, Timoschenko MV, Suleimanova AV. The effect of rivaroxaban low doses on the stable angina of the II–III functional class clinical manifestations and the quality of life in patients with ischemic heart disease. Kardiologiya. 2021;61(9):47–51. (In Russ.) https://doi.org/10.18087/cardio.2021.9.n1696.

31. Atzemian N, Kareli D, Ragia G, Manolopoulos VG. Distinct pleiotropic effects of direct oral anticoagulants on cultured endothelial cells: a comprehensive review. Front Pharmacol. 2023;14:1244098. https://doi.org/10.3389/fphar.2023.1244098.

32. Anand SS, Eikelboom JW, Dyal L, Bosch J, Neumann C, Widimsky P et al. COMPASS Trial Investigators. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. J Am Coll Cardiol. 2019;73(25):3271–3280. https://doi.org/ 10.1016/j.jacc.2019.02.079.

33. Khan SU, Khan MZ, Asad Zua, Valavoor S, Khan MU, Khan MS et al. Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis. J Thromb Thrombolysis. 2020;50(4):913–920. https://doi.org/10.1007/s11239-020-02114-7.

34. Fox KAA, Aboyans V, Debus ES, Zeymer U, Cowie MR, Patel M et al. Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. Eur Heart J Cardiovasc Pharmacother. 2022;8(8):825–836. https://doi.org/10.1093/ehjcvp/pvac028.